But what the investors in RLFTF are touting is tha

Quote:

---

Briefly, inhalation of single doses, even at high concentrations did not produce Aviptadil levels in the plasma of animals. Repeated dose inhalation of Aviptadil for 14-days may lead to elevated plasma concentrations in monkeys. However, the measured Aviptadil- level in monkeys may contain mainly not-pharmacologically active metabolites of Aviptadil which are detected by the used radio immune assay in addition to the entire molecule. Reason for this assumption is that the high measured concentration did not cause any expected pharmacodynamic effect.

---